AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3176071 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (95%, 0.84 ml/kg) as positive control
Number of subjects: 137
Study 3176071 — intervention group
Group type: COMPARATOR
Intervention: Chemical-placebo
Number of subjects: 137
Study 31493942 — intervention group
Group type: EXPERIMENTAL
Intervention: RIMO intervention
Number of subjects: 33
Study 31493942 — intervention group
Group type: COMPARATOR
Intervention: Passive referral control
Number of subjects: 33
Study 30184254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (2.5 ml)
Number of subjects: 60
Study 30184254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (5.0 ml)
Number of subjects: 60
Study 30184254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (10 ml)
Number of subjects: 60
Study 30184254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (15 ml)
Number of subjects: 60
Study 30184254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (20 ml)
Number of subjects: 60
Study 26032281 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (α2-adrenoceptor antagonist)
Number of subjects: 22
Study 26032281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24385236 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 80 mg QD for 2 weeks followed by 120 mg QD for 2 weeks
Number of subjects: 60
Study 24385236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24385236 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002
Number of subjects: 60
Study 22197589 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers in the polyethylene as reference segment
Number of subjects: 31
Study 22197589 — intervention group
Group type: COMPARATOR
Intervention: Markers in the periacetabular bone as reference segment
Number of subjects: 31
Study 20411425 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-air insufflation limited to the rectum and sigmoid colon (group C)
Number of subjects: 250
Study 18824288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (IV injection of 17 mL over 17 seconds)
Number of subjects: 750
Study 18824288 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (IV injection of 17 mL over 17 seconds)
Number of subjects: 750
Study 16015004 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (Q)
Number of subjects: 73
Study 16015004 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (A)
Number of subjects: 73
Study 16015004 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril and Amlodipine (Q&A)
Number of subjects: 73
Study 12359651 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100 micro g, twice daily)
Number of subjects: 61
Study 11063439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose diet (17% of energy as fructose)
Number of subjects: 24
Study 11063439 — intervention group
Group type: COMPARATOR
Intervention: Glucose diet (nearly devoid of fructose)
Number of subjects: 24
Study 8836653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin therapy
Number of subjects: 33
Study 8836653 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 33
Study 8836653 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study 1467074 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg i.m. 12-hourly for 2 days
Number of subjects: 20
Study 1467074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6584028 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg prostaglandin E2 vaginal pessaries
Number of subjects: 202
Study 6584028 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 202
Study 6584028 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (after prostaglandin)
Number of subjects: 202
Study 6584028 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 202
Study 30710389 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM
Number of subjects: 66
Study 30710389 — intervention group
Group type: COMPARATOR
Intervention: DBBM-C
Number of subjects: 66
Study 29508715 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of montelukast for 2 weeks followed by 10 mg of montelukast for 2 weeks
Number of subjects: 50
Study 29508715 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of prednisolone for 2 weeks followed by 10 mg of montelukast for 2 weeks
Number of subjects: 50
Study 29508715 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of montelukast for 2 weeks
Number of subjects: 50
Study 27245789 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, computer-tailored intervention with personalized feedback and tips
Number of subjects: 213
Study 27245789 — intervention group
Group type: COMPARATOR
Intervention: Generic web-based advice with tips
Number of subjects: 213
Study 27245789 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 213
Study 24389416 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronate 5mg i.v. annually
Number of subjects: 60
Study 24389416 — intervention group
Group type: COMPARATOR
Intervention: ibandronate 3mg i.v. every 3 months
Number of subjects: 60
Study 22878803 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg/hydrochlorothiazide 12.5 mg
Number of subjects: 0
Study 22878803 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 5 mg
Number of subjects: 0
Study 20230461 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.4 mg
Number of subjects: 11
Study 20230461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17510755 — intervention group
Group type: EXPERIMENTAL
Intervention: SEDS salbutamol sulfate (three batches)
Number of subjects: 23
Study 17510755 — intervention group
Group type: COMPARATOR
Intervention: Asmasal inhaler (micronized drug)
Number of subjects: 23
Study 15653940 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 1801
Study 15653940 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study 11208637 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel ventilatory support (BVS)
Number of subjects: 13
Study 11208637 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow oxygen (LFO2)
Number of subjects: 13
Study 11208637 — intervention group
Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 13
Study 8996294 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral ramipril (n = 20)
Number of subjects: 35
Study 8996294 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control, n = 15)
Number of subjects: 35
Study 8488685 — intervention group
Group type: EXPERIMENTAL
Intervention: Theospirex retard 300 mg (single evening dose)
Number of subjects: 19
Study 8488685 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (400 mg, single evening dose)
Number of subjects: 19
Study 8488685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations (Theospirex retard and reference preparation)
Number of subjects: 19
Study 2963686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 0
Study 2963686 — intervention group
Group type: EXPERIMENTAL
Intervention: Early angiography
Number of subjects: 0
Study 2963686 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 2575875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil-pancuronium
Number of subjects: 120
Study 2575875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil-vecuronium
Number of subjects: 120
Study 2575875 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 120
Study 2575875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30088199 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverages
Number of subjects: 121
Study 30088199 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo beverages
Number of subjects: 121
Study 30088199 — intervention group
Group type: COMPARATOR
Intervention: Control beverages
Number of subjects: 121
Study 28272718 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP (biodegradable nasopore)
Number of subjects: 72
Study 28272718 — intervention group
Group type: COMPARATOR
Intervention: Merocel (Merocel Hemox 10 cm)
Number of subjects: 72
Study 25439606 — intervention group
Group type: EXPERIMENTAL
Intervention: AGV
Number of subjects: 276
Study 25439606 — intervention group
Group type: COMPARATOR
Intervention: BGI
Number of subjects: 276
Study 23245456 — intervention group
Group type: EXPERIMENTAL
Intervention: Team and leaders-directed strategy
Number of subjects: 67
Study 23245456 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art strategy
Number of subjects: 67
Study 21321419 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir
Number of subjects: 30
Study 21321419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 30
Study 19301059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (80 mg i.v. bolus followed by 8 mg/h for 1 h)
Number of subjects: 18
Study 19301059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19301059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 18
Study 16740419 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 0
Study 15578473 — intervention group
Group type: EXPERIMENTAL
Intervention: target-controlled propofol (1-8 microg/mL plasma target concentration)
Number of subjects: 360
Study 15578473 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane (1%-4% end-tidal concentration)
Number of subjects: 360
Study 15578473 — intervention group
Group type: COMPARATOR
Intervention: isoflurane (0.5%-2% end-tidal concentration)
Number of subjects: 360
Study 11382369 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (2g/day orally) for 6 months
Number of subjects: 155
Study 11382369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 11382369 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine
Number of subjects: 155
Study 8993260 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat acid-base management
Number of subjects: 0
Study 8993260 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-stat acid-base management
Number of subjects: 0
Study 8993260 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative changes in CBF and VMCA
Number of subjects: 0
Study 8357499 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging
Number of subjects: 0
Study 8357499 — intervention group
Group type: COMPARATOR
Intervention: Dieting
Number of subjects: 0
Study 8357499 — intervention group
Group type: COMPARATOR
Intervention: Exercise without dieting
Number of subjects: 0
Study 8357499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prudent diet (low fat, low cholesterol) + exercise
Number of subjects: 0
Study 8357499 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise addition to dietary change
Number of subjects: 0
Study 2442541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 179
Study 2442541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 30679439 — intervention group
Group type: EXPERIMENTAL
Intervention: Early limited ART (part of the CHER trial)
Number of subjects: 1
Study 30679439 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1
Study 26934057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff inflation at 140 mmHg
Number of subjects: 6
Study 26934057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff inflation at 180 mmHg
Number of subjects: 6
Study 26934057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff deflation after occlusion
Number of subjects: 6
Study 26934057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff inflation pressures (140, 160, 180 mmHg)
Number of subjects: 6
Study 24531357 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus autograft (ST)
Number of subjects: 19
Study 24531357 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus + gracilis (ST/G)
Number of subjects: 19
Study 23725526 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g/day of dietary fiber for 12 weeks
Number of subjects: 30
Study 22050131 — intervention group
Group type: COMPARATOR
Intervention: HOT (40.2 ± 0.3 °C)
Number of subjects: 11
Study 22050131 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD (20.4 ± 0.7 °C)
Number of subjects: 11
Study 19692210 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg i.v. once daily
Number of subjects: 364
Study 19692210 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 2 g i.v. once daily plus Metronidazole 500 mg i.v. twice daily
Number of subjects: 364
Study 16530145 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care medical record
Number of subjects: 443
Study 16530145 — intervention group
Group type: COMPARATOR
Intervention: Maternal interview
Number of subjects: 443
Study 15600227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (Medication + CBT for 10 weeks)
Number of subjects: 6
Study 15600227 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping (Medication for 5 weeks, CBT introduced at week 4, medication withdrawal after 5 weeks)
Number of subjects: 6
Study 15600227 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication -> CBT (Medication alone for 5 weeks, then CBT alone for 5 weeks)
Number of subjects: 6
Study 11725446 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching booklet with humor
Number of subjects: 50
Study 11725446 — intervention group
Group type: COMPARATOR
Intervention: Teaching booklet without humor
Number of subjects: 50
Study 11725446 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without humor)
Number of subjects: 50
Study 9652561 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-TV (titre 4x10(5) plaque-forming units)
Number of subjects: 2398
Study 9652561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2398
Study 8215749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine, 150 mg twice daily
Number of subjects: 496
Study 8215749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 8215749 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine and Placebo
Number of subjects: 496
Study 3300761 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan treatment
Number of subjects: 648
Study 3300761 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide treatment
Number of subjects: 648
Study 30875336 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CTB protocol (N=100)
Number of subjects: 217
Study 30875336 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (N=161)
Number of subjects: 217
Study 28954640 — intervention group
Group type: EXPERIMENTAL
Intervention: beta2-1 fructan (3x5 g/d for 28 days)
Number of subjects: 30
Study 28954640 — intervention group
Group type: COMPARATOR
Intervention: maltodextrin (3x5 g/d for 28 days)
Number of subjects: 30
Study 25082070 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy prior to ICSI
Number of subjects: 193
Study 25082070 — intervention group
Group type: COMPARATOR
Intervention: ICSI alone (without hysteroscopy)
Number of subjects: 193
Study 22936530 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas Dementia Crisis Bridge Project intervention
Number of subjects: 0
Study 21694627 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (40 mg)
Number of subjects: 18
Study 21694627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (75 mg)
Number of subjects: 18
Study 21694627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18266566 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative volume replacement
Number of subjects: 210
Study 18266566 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative volume replacement
Number of subjects: 210
Study 16931978 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial blocker
Number of subjects: 60
Study 16931978 — intervention group
Group type: COMPARATOR
Intervention: Double-lumen tube
Number of subjects: 60
Study 16931978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 12937193 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (low blood alcohol concentration, around half the UK legal driving limit)
Number of subjects: 12
Study 12937193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Number of subjects: 12
Study 12937193 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alcohol and sleep restriction
Number of subjects: 12
Study 12937193 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no alcohol)
Number of subjects: 12
Study 10937515 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 45
Study 8606273 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 38
Study 1290169 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (ATIII) replacement therapy before the induction of anaesthesia and throughout surgery
Number of subjects: 29
Study 1290169 — intervention group
Group type: COMPARATOR
Intervention: No Antithrombin III replacement therapy
Number of subjects: 29
Study 6237663 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H received alcuronium and were ventilated artificially using 0.5% halothane and nitrous oxide in oxygen
Number of subjects: 56
Study 6237663 — intervention group
Group type: COMPARATOR
Intervention: Group E breathed spontaneously a mixture of enflurane and nitrous oxide in oxygen
Number of subjects: 56
Study 30673543 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg three times per day) in combination with carbidopa (25 mg three times per day) for 80 weeks
Number of subjects: 445
Study 30673543 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 40 weeks followed by levodopa in combination with carbidopa for 40 weeks
Number of subjects: 445
Study 30673543 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (early-start group)
Number of subjects: 445
Study 30673543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (delayed-start group)
Number of subjects: 445
Study 30673543 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa in combination with carbidopa
Number of subjects: 445
Study 29494727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 240
Study 29494727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab and laser combination therapy
Number of subjects: 240
Study 29494727 — intervention group
Group type: COMPARATOR
Intervention: Laser monotherapy
Number of subjects: 240
Study 25217447 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousing picture stimuli
Number of subjects: 95
Study 25217447 — intervention group
Group type: COMPARATOR
Intervention: Non-arousing picture stimuli
Number of subjects: 95
Study 23990646 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation treatment for depression (BATD)
Number of subjects: 80
Study 23990646 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 80
Study 21415158 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels in the highest quartile (>122 pmol/L)
Number of subjects: 1241
Study 19480671 — intervention group
Group type: EXPERIMENTAL
Intervention: group‐based lifestyle rehabilitation programme
Number of subjects: 180
Study 19480671 — intervention group
Group type: COMPARATOR
Intervention: conventional individual counselling
Number of subjects: 180
Study 17550216 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (GLAR; n=74)
Number of subjects: 142
Study 17550216 — intervention group
Group type: COMPARATOR
Intervention: NPH/semilente insulin (NPH; n=68)
Number of subjects: 142
Study 14504683 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (0, 10, 20 and 30 mg)
Number of subjects: 7
Study 14504683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (45 mg)
Number of subjects: 7
Study 14504683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 mg)
Number of subjects: 7
Study 11816230 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 49
Study 11816230 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 9731558 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23
Study 9731558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9071430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5 mg twice/day (D)
Number of subjects: 52
Study 9071430 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 750 mg/day (M750)
Number of subjects: 52
Study 9071430 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 750 mg/day + dronabinol 2.5 mg twice/day (M750+D)
Number of subjects: 52
Study 9071430 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 250 mg/day + dronabinol 2.5 mg twice/day (M250+D)
Number of subjects: 52
Study 9071430 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 52
Study 9071430 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (M750)
Number of subjects: 52
Study 9071430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 52
Study 9071430 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 52
Study 1685532 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% intraocular dapiprazole
Number of subjects: 120
Study 1685532 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% intraocular dapiprazole
Number of subjects: 120
Study 1685532 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% intraocular dapiprazole
Number of subjects: 120
Study 1685532 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 120
Study 7069205 — intervention group
Group type: EXPERIMENTAL
Intervention: delta MTCI
Number of subjects: 162
Study 7069205 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in malar temperature
Number of subjects: 162